|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
DE69033109T2
(de)
|
1989-07-06 |
1999-11-18 |
The Regents Of The University Of California, Oakland |
Rezeptoren für fibroblasten-wachstumsfaktoren
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
AU3494397A
(en)
|
1996-06-18 |
1998-01-07 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Fibroblast growth factor receptor activating gene i and related compositions and methods
|
|
EP0994903B1
(en)
|
1997-06-24 |
2005-05-25 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
EP1125584A4
(en)
|
1998-10-30 |
2005-01-12 |
Takeda Chemical Industries Ltd |
PREPARATIONS CONTAINING BETACELLULIN PROTEIN
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2369292C
(en)
|
1999-04-09 |
2010-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of modulating the activity of functional immune molecules
|
|
CN1308347C
(zh)
|
1999-04-28 |
2007-04-04 |
德克萨斯大学董事会 |
用于通过选择性抑制vegf来治疗癌症的组合物和方法
|
|
WO2001029246A1
(fr)
|
1999-10-19 |
2001-04-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'un polypeptide
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
EA013563B1
(ru)
|
2000-10-06 |
2010-06-30 |
Киова Хакко Кирин Ко., Лтд. |
Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
CA2455365C
(en)
|
2001-08-03 |
2014-07-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CN101357943A
(zh)
*
|
2001-10-25 |
2009-02-04 |
杰南技术公司 |
糖蛋白组合物
|
|
ATE430580T1
(de)
|
2001-10-25 |
2009-05-15 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
ES2363765T3
(es)
|
2002-01-31 |
2011-08-16 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonistas de fgfr.
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
ES2362419T3
(es)
|
2002-04-09 |
2011-07-05 |
Kyowa Hakko Kirin Co., Ltd. |
Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
|
|
WO2003085119A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
CN1930288B
(zh)
|
2002-04-09 |
2012-08-08 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
CA2766627C
(en)
*
|
2003-05-02 |
2019-12-03 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
|
CA2762955A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Imclone Llc |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
HUE033349T2
(en)
|
2003-10-22 |
2017-11-28 |
Keck Graduate Inst |
Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
CA2550245A1
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
WO2005115363A2
(en)
|
2004-05-25 |
2005-12-08 |
Yale University |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
WO2006081430A2
(en)
|
2005-01-27 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
BRPI0607203A2
(pt)
*
|
2005-02-18 |
2009-08-25 |
Medarex Inc |
anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
CA2648021A1
(en)
|
2006-03-31 |
2007-10-11 |
Ordway Research Institute, Inc. |
Prognostic and diagnostic method for cancer therapy
|
|
JP2009536834A
(ja)
|
2006-05-12 |
2009-10-22 |
ジェネンテック・インコーポレーテッド |
癌の診断及び治療のための方法及び組成物
|
|
US20100173323A1
(en)
*
|
2006-06-09 |
2010-07-08 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
US7750124B2
(en)
|
2006-09-29 |
2010-07-06 |
Oncomed Pharmaceuticals, Inc. |
Anti-human DLL4 antibodies and compositions
|
|
WO2008052796A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
AR064464A1
(es)
|
2006-12-22 |
2009-04-01 |
Genentech Inc |
Anticuerpos anti - receptor del factor de crecimiento insulinico
|
|
CA2676529C
(en)
|
2007-01-24 |
2014-03-25 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
JP2010525301A
(ja)
|
2007-03-23 |
2010-07-22 |
ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート |
子宮内膜癌および前癌の診断、分類および治療の方法
|
|
CA2682382A1
(en)
*
|
2007-03-28 |
2008-10-09 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
US20110091473A1
(en)
|
2007-10-22 |
2011-04-21 |
Genmab A/S |
Novel antibody therapies
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
|
WO2009119173A1
(ja)
|
2008-03-26 |
2009-10-01 |
日本電気株式会社 |
無線リソースの制御方法、無線局装置、無線局制御プログラムを格納した記録媒体、及び無線通信システム
|
|
WO2009151448A1
(en)
*
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
DK2842573T3
(en)
*
|
2008-11-07 |
2017-10-30 |
Galaxy Biotech Llc |
Monoclonal antibodies to fibroblast growth factor receptor 2
|
|
WO2011025814A1
(en)
|
2009-08-25 |
2011-03-03 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
KR101808602B1
(ko)
*
|
2009-10-07 |
2017-12-13 |
마크로제닉스, 인크. |
푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
|
|
PT2488554T
(pt)
*
|
2009-10-14 |
2019-09-13 |
Humanigen Inc |
Anticorpos para epha3
|
|
WO2011088196A2
(en)
|
2010-01-14 |
2011-07-21 |
Yale University |
Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
|
|
EP2547698B1
(en)
|
2010-03-14 |
2015-07-29 |
The Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
SG185487A1
(en)
|
2010-05-11 |
2012-12-28 |
Aveo Pharmaceuticals Inc |
Anti-fgfr2 antibodies
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
EP2603521A4
(en)
|
2010-08-12 |
2014-10-01 |
Attogen Inc |
ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
|
|
US20120258496A1
(en)
*
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
WO2012045085A1
(en)
*
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
SG11201403085PA
(en)
|
2011-12-14 |
2014-10-30 |
Seattle Genetics Inc |
Fgfr antibody drug conjugates (adcs) and the use thereof
|
|
ES2689269T3
(es)
*
|
2012-03-30 |
2018-11-13 |
The Regents Of The University Of California |
La terapia anti-EMP2 reduce las células madre cancerosas
|
|
CA2870126C
(en)
|
2012-04-09 |
2020-10-27 |
Daiichi Sankyo Company, Limited |
Anti-fgfr2 antibody
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
JPWO2014007369A1
(ja)
|
2012-07-05 |
2016-06-02 |
国立研究開発法人国立がん研究センター |
Ｆｇｆｒ２融合遺伝子
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
AU2014259956A1
(en)
|
2013-05-01 |
2015-11-12 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
|
WO2014197937A1
(en)
|
2013-06-13 |
2014-12-18 |
University Of South Australia |
Methods for detecting prostate cancer
|
|
PE20160190A1
(es)
|
2013-08-01 |
2016-04-28 |
Five Prime Therapeutics Inc |
Anticuerpos anti-fgfr2iiib afucosilados
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
AU2015210886A1
(en)
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
CN107108740B
(zh)
|
2014-11-05 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
抗fgfr2/3抗体及其使用方法
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
BR112018010410A8
(pt)
|
2015-11-23 |
2019-02-26 |
Five Prime Therapeutics Inc |
método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
|
|
CN110621336B
(zh)
|
2017-05-16 |
2024-05-14 |
戊瑞治疗有限公司 |
癌症治疗中抗fgfr2抗体与化学治疗剂的组合
|